Therapeutic apheresis, a novel approach for immunodisorders, has been used in the last
decade for the treatment of ulcerative colitis with promising result, and represents an …

Ulcerative colitis and Crohn's disease are inflammatory bowel diseases with a chronic
relapsing course. Management of both conditions is far from being fully satisfactory. For this …

Intense infiltration of the intestinal mucosa by activated leukocytes is a hallmark of
inflammatory bowel disease (IBD). Therefore, removal of circulating leukocytes may be an …

Objective. Selective leukocyte apheresis is a new type of non-pharmacological treatment for
patients with active ulcerative colitis and Crohn's disease. Preliminary data have indicated …

Ulcerative colitis (UC) and Crohn's disease (CD) are the major forms of idiopathic
inflammatory bowel disease (IBD). Both UC and CD are debilitating chronic disorders that …

Leukocytapheresis, device used to remove leukocytes from peripheral circulation, has been
approved for the treatment of active ulcerative colitis (UC) by the Ministry of Health and …

Cellular apheresis is now established as a rational therapeutic procedure in certain
inflammatory and autoimmune diseases, particularly in inflammatory bowel diseases, but the …

Reports describing the successful treatment of active, steroid-resistant inflammatory bowel
disease (IBD) with leucocytapheresis first emerged about 10 years ago. Since then, several …

Initially used to treat rheumatoid arthritis, nonselective therapeutic leukocytapheresis was
applied to the treatment of inflammatory bowel disease (IBD) as early as the 1980s. Since …

Recently, selective granulocytapheresis (Adacolumn) has appeared as a new treatment for
patients with inflammatory bowel disease. This study sought to determine predictors of …